Indian Pharmaceutical Sector Poised to Double: Minister Goyal Launches Call for Global Partnerships and Innovation

Indian Pharmaceutical Sector Poised to Double: Minister Goyal Launches Call for Global Partnerships and Innovation​

Union Minister of Commerce & Industry Shri Piyush Goyal has issued a major invitation to global pharmaceutical companies, projecting that India's pharma industry could double its size within the next five years. Addressing stakeholders at the Global Ambassador Meet on Pharmaceutical Sector in New Delhi, Mr. Goyal stressed that while affordable medicine remains paramount, India is actively transitioning toward innovation-driven products.

Currently valued at approximately $60 billion, the sector represents a crucial component of global healthcare supply chains. The Minister outlined a vision where India serves not just as a manufacturing hub, but as an innovator and technology partner to nations worldwide.

Economic Resilience Fuels Pharma Ambitions​

Shri Goyal highlighted that despite significant global turbulence, including conflicts in West Asia and Ukraine and the imposition of 50 per cent tariffs by the United States, India continues to demonstrate remarkable economic growth. He noted that the Indian economy achieved a solid growth rate of 7.7 per cent at constant prices during the fiscal year ending March 2026.

He further affirmed India's commitment to global trade access, stating that his nation is prepared to grant preferential market entry to high-quality innovative products from partner countries. This market preparedness is underscored by India's recent expansion into nine Free Trade Agreements and agreements covering over 50 nations.

Commitment to Affordability Through Generics​

A central pillar of the Indian pharmaceutical industry remains its commitment to serving millions of patients globally through affordable medicines. While generics account for a significant volume, reportedly 80-90 per cent of sales in the United States, they represent only about 10-15 per cent of the value.

This dynamic underscores India's core competitive advantage: delivering essential healthcare at sustainable prices. The Minister attributed this affordability to not only the talent pool but also significantly lower operating costs compared to advanced economies.

Trust Innovation and Partnerships Define Growth​

The Ministry articulated three defining strengths that position Indian pharma for massive future growth: trust, innovation, and strategic partnerships. These pillars govern India's journey from a generic manufacturer to a global innovator.

On 'Trust,' Mr. Goyal stated that the industry has aligned its Good Manufacturing Practices framework with international standards. Currently, approximately 65-70 per cent of the World Health Organization vaccine requirements are sourced from India. Furthermore, ten of the world's 25 largest generic pharmaceutical companies operate their base in India.

Accelerating Innovation and Global Collaboration​

In terms of 'Innovation,' the Minister pointed to a nearly 100 per cent increase in patent filings within recent years. He highlighted the proactive efforts through programs like Biopharma Shakti and referenced a $10 billion government initiative supporting innovation across key sectors, including pharmaceuticals.

Inviting greater collaboration, Mr. Goyal appealed to global firms to establish a stronger presence in India. He noted that companies can benefit immensely from the opportunities presented by India's market of 1.4 billion people, rapid income growth, and its expanding middle class.

A Philosophy Rooted in Global Care​

Citing the ancient Sanskrit expression "Sarve Santu Niramaya" ("May all beings be free from illness"), Mr. Goyal stressed that India views healthcare as a shared global responsibility. This ethos has been profoundly tested by past crises, including the COVID-19 pandemic.

He commended Indian companies for their resilience during the health emergency, noting they served not only domestic needs but also the Global South and developing nations. He clarified that temporary export restrictions were imposed strictly to ensure equitable availability at affordable prices, preventing profiteering by entities with vast financial resources.